WCN26-3295 ERTHROCYTOSIS FOLLOWING SGLT2 INHIBITOR (GLIFLOZIN) THERAPY IN RENAL PATIENTS – A CASE SERIES

Read full text Summarise with VIRAT
Authors: Dipankar M. Bhowmik, Ranjan Kumar Sahoo, Sachin Gautam, S. Bagchi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

SGLT2 inhibitors (SGLT2i) or gliflozins are nowadays commonly prescribed in renal patients for nephroprotection. Erythrocytosis or polycythemia is one of its side effects, which is not well known. There has been reports in some studies related to its usage in heart failure patients. However, there is not much literature on this topic in renal patients. We present a case series of six patients with renal disease, who developed erythrocytosis after treatment with dapagliflozin.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Diabetes Treatment and Management Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104208–104208
Publication date
25 March 2026
Language
EN